康弘药业(002773.SZ)：收到药物临床试验补充申请批准通知书

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) announced that its wholly-owned subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of Kangbai Xip injection for eye use [1] Group 1: Drug Information - Drug Name: Kangbai Xip Injection for Eye Use [1] - Dosage Form: Injection [1] - Indications: Treatment for neovascular (wet) age-related macular degeneration (nAMD) and vision impairment due to macular edema secondary to retinal vein occlusion (RVO), including branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) [1] - Acceptance Numbers: CXSB2500193, CXSB2500194 [1] - Approval Conclusion: Permission granted to conduct clinical trials [1]